Notícias

The healthcare company said the agreement covers the remaining ovarian talc litigation in federal multidistrict litigation proceedings and related state court cases.

By Dietrich Knauth NEW YORK, July 27 (Reuters) - Johnson & Johnson said on Monday it has reached a $5.5 billion settlement that will resolve tens of thousands of lawsuits alleging its baby powder and

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its full-year guidance and is on track to surpass $100 billion […]

The drugmaker's rapid stock gains have led to a premium valuation, forcing investors to question its capacity for future growth.

UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.

Here is a way to get paid a significant income stream today from Eli Lilly stock, which you keep no matter what, while setting a price far below current levels where you would be willing to buy.

Shares of Legend Biotech fell 14% Monday after the company announced that CEO Ying Huang stepped down and left the board. Legend said in a regulatory filing that Huang’s resignation was not the result of a disagreement with the company, but didn’t say anything more about why he left. Huang said he was departing the company to work with a venture fund focusing on drug development.

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.

A 2.8% Social Security raise barely covers a trip to the grocery store, so retirees are quietly rebuilding their paychecks around five dividend stocks with track records stretching back through every recession of the past two decades.

Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump’s financial disclosures released earlier this year. Now a top J&J executive is heading the other direction. The Insider Sale EVP of Global Corporate Affairs Vanessa Broadhurst sold 23,054 shares on July 20, a transaction worth close to […]

GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results.

The company that used to reassure you with its sheer breadth now leads with a push to dominate oncology, and a holder who bought a diversified compounder should notice the bet has changed shape.

Stopping work at 62 while waiting for a bigger Social Security check sounds clean on paper, but the math gets complicated fast when a portfolio has to carry the entire household for years. Here is how much capital different yield strategies actually require, and which tradeoffs could quietly wreck the plan.

Generating $48,000 a year in dividends sounds like a retirement fantasy until you see how the math actually splits across three very different yield strategies, each demanding a radically different amount of starting capital and carrying its own hidden cost.

Both have very promising futures.

A $2 million retirement portfolio can generate wildly different income streams depending on where you put it, and choosing the wrong tier does not just leave money on the table. It can quietly eat your principal alive while you think you are getting rich.

Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.

Management's plain health care label has slipped out of the lead, and the business now on a separation clock is the one that finally started working.

Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer’s top healthcare stocks even though the shares have been lackluster. They are up by a modest 27% year-to-date, with most of the gains having come since mid-June. Since June 18th, Johnson & Johnson (NYSE:JNJ)’s stock is up by 15%. As the shares struggled in […]

Stripe is reportedly circling PayPal in a deal that could end a frustrating run for the fintech giant, but is it a good enough deal?

<body><p>STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.</p><p>The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.</p><p>Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.</p><p>Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called "safer parts of the market."</p><p>"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well."</p><p>The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.</p><p>Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.</p><p>Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.</p></body>

Johnson & Johnson reported highly positive interim Phase 3 results for the TECVAYLI + TALVEY combination in relapsed or refractory multiple myeloma. The trial was unblinded early after the regimen significantly reduced the risk of disease progression and death. The data are expected to inform future regulatory discussions and potential changes to treatment standards in multiple myeloma. For investors tracking Johnson & Johnson (NYSE:JNJ), this oncology update comes with the stock trading...

Replacing a Social Security check with dividend income sounds straightforward until you realize the yield you chase changes the capital required by more than a million dollars. The tier you pick carries tradeoffs most income investors only discover after the fact.

Companies raising guidance, particularly on the earnings front, always deserve some level of attention from investors. Recently, JNJ, GM, and ABT have all raised their outlooks.

JNJ's Innovative Medicine unit posts strong Q2 growth despite Stelara's patent loss. See what's fueling momentum into H2 2026.

A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.

The U.S. Food and Drug Administration on Wednesday granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery...

The robotic surgery leader's shares have pulled back, forcing investors to weigh a solid recovery record against new questions in its most important market.

Fixed-rate bonds cannot outrun inflation over a 25-year retirement, yet most boomers keep reaching for them anyway. Three companies have raised their dividends for between 50 and 70 consecutive years and may offer a more durable solution, though each carries a hidden transition risk that income investors need to weigh.